Kristina Wang is the Head of Corporate Development at Zola Therapeutics, a biotech company pioneering next-generation innate immune modulators for oncology and autoimmune diseases. She brings expertise in life sciences investing, company formation, and business development in early-stage biotech. Prior to Zola, Kristina held strategic and operational roles at venture-backed biotech, leading efforts in fundraising, partnerships, and strategy. She started her career in healthcare investment banking and venture capital. Kristina holds a BSE from University of Pennsylvania, an MS from Harvard Medical School, and an MBA from Harvard Business School.